Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

20+ years

Phase:

PHASE2

Brief Summary

The primary objective was to evaluate the safety of dabigatran etexilate(BIBR 1048) administered orally at doses of 110 and 150 mg, twice daily, for 12 weeks in patients with non-valvular atrial fibri...

Eligibility Criteria

Inclusion

  • Inclusion criteria Inclusion criteria
  • Patients with non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
  • Patients who had additional risk factor for thromboembolism; one or more of the following conditions/events:
  • Hypertension
  • Diabetes mellitus
  • Left-side heart failure
  • A previous ischemic stroke or transient ischemic attack
  • Age 75 years or older
  • A history of coronary artery diseases
  • Exclusion criteria Exclusion criteria
  • Patients diagnosed as having a valvular heart disease by echocardiography, or patients who had a history of prosthetic valve replacement or valve surgery
  • Patients who were to receive electric defibrillation or pharmacological defibrillation during the study period
  • Patients who developed stroke or transient ischemic attack within 30 days before the date of informed consent
  • Patients who developed myocardial infarction or were admitted to hospital due to acute coronary syndrome or for percutaneous transluminal coronary angioplasty within 3 months before the date of informed consent or patients underwent coronary stenting within 6 months before the date of informed consent
  • Patients with atrial myxoma or left ventricular thrombosis
  • Patients with contraindication to anticoagulant therapies
  • Patients scheduled for major surgery or invasive procedure
  • Patients having major bleeding from non-gastrointestinal organs within 6 months before the date of informed consent
  • Patients with uncontrolled hypertension

Exclusion

    Key Trial Info

    Start Date :

    November 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    174 Patients enrolled

    Trial Details

    Trial ID

    NCT01136408

    Start Date

    November 1 2005

    Last Update

    March 19 2014

    Active Locations (28)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 7 (28 locations)

    1

    1160.49.024 Boehringer Ingelheim Investigational Site

    Aki-gun, Hiroshima, Japan

    2

    1160.49.025 Boehringer Ingelheim Investigational Site

    Fukuoka, Fukuoka, Japan

    3

    1160.49.026 Boehringer Ingelheim Investigational Site

    Fukuoka, Fukuoka, Japan

    4

    1160.49.021 Boehringer Ingelheim Investigational Site

    Himeji, Hyogo, Japan